Please enter full name.
Please enter product name.
Select Industry.
Email address already exists
Please enter Password.
Enter Conatct number.
Please enter company name.
Please enter date.
Enter Message
By Signing Up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services
Thank you, your message has been sent.
Invalid Email.
Building A, NO.688,Qiushi Road,Jinshan District,Shanghai,shanghai,China China
Raltegravir (MK-0518) is a potent inhibitor of human immunodeficiency virus (HIV) integrase and is clinically effective against viruses resistant to o
871038-72-1, raltegravir, raltegravir K salt, N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl)-5-met
Axitinib is an investigational drug being developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.The drug
Axitinib is an investigational drug being developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.
In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory
Bendamustine was first synthesized in 1963 by Ozegowski and Krebs in East Germany (the former German Democratic Republic).
A panel of four CCR5 monoclonal antibodies (mAbs) recognizing different epitopes on CCR5 was examined in CCR5-mediated cell-cell fusion assay
الشخص الذي يمكن الاتصال به Mr. James DGM
عنوان Building A, NO.688,Qiushi Road,Jinshan District, Shanghai, shanghai
We will contact you soon .
Please select at least one Buyer/Supplier.
Please enter name.
Please select industry.
Enter Password
Please select country.
Please select state.
Please select city.
Please Enter Message.
